Condition
ICC
Total Trials
6
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 6 trials
Late-Stage Pipeline
17%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
5Total
P 2 (4)
P 3 (1)
Trial Status
Unknown2
Withdrawn2
Recruiting1
Not Yet Recruiting1
Clinical Trials (6)
Showing 6 of 6 trials
NCT07364305Phase 2RecruitingPrimary
HAIC Combined With Immune Therapy for Advanced, Non-Resectable ICC
NCT06447454Not Yet RecruitingPrimary
Combining Chemoradiotherapy With Sintilimab in First-Line ICC
NCT04769908Phase 2UnknownPrimary
Systemic Chemotherapy, Lenvatinib Plus Sintilimab for ICC With Distant Metastasis
NCT04398927Phase 2WithdrawnPrimary
Systemic Chemotherapy Plus PD-1 for Metastasis ICC
NCT04682249Phase 2WithdrawnPrimary
Systemic Chemotherapy, Apatinib Plus Sintilimab for Metastasis ICC
NCT03940378Phase 3UnknownPrimary
Treatment of Advanced Intrahepatic Cholangiocarcinoma
Showing all 6 trials